Publications
Detailed Information
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Lee, Kyung-Hun | - |
dc.contributor.author | Choi, Yunhee | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Koo, Nam Hee | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Yoo, Keun-Young | - |
dc.contributor.author | Park, Seonyang | - |
dc.contributor.author | Kim, Byoung Kook | - |
dc.date.accessioned | 2010-01-11T02:16:30Z | - |
dc.date.available | 2010-01-11T02:16:30Z | - |
dc.date.issued | 2007-04-24 | - |
dc.identifier.citation | J Korean Med Sci. 2007 Apr;22(2):227-34. | en |
dc.identifier.issn | 1011-8934 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17449929 | - |
dc.identifier.uri | https://hdl.handle.net/10371/29281 | - |
dc.description.abstract | We compared the outcomes of allogeneic hematopoietic stem cell transplantation using reduced intensity and myeloablative conditioning for the treatment of patients with advanced hematological malignancies. A total of 75 adult patients received transplants from human leukocyte antigen-matched donors, coupled with either reduced intensity (n=40; fludarabine/melphalan, 28; fludarabine/cyclophosphamide, 12) or myeloablative conditioning (n=35, busufan/cyclophosphamide). The patients receiving reduced intensity conditioning were elderly, or exhibited contraindications for myeloablative conditioning. Neutrophil and platelet engraftment occurred more rapidly in the reduced intensity group (median, 9 days vs. 18 days in the myeloablative group, p<0.0001; median 12 days vs. 22 days in the myeloablative group, p=0.0001, respectively). Acute graft-versus-host disease (>or=grade II) occurred at comparable frequencies in both groups, while the incidence of hepatic veno-occlusive disease was lower in the reduced intensity group (3% vs. 20% in the myeloablative group, p=0.02). The overall 1-yr survival rates of the reduced intensity and myeloablative group patients were 44% and 15%, respectively (p=0.16). The results of present study indicate that patients with advanced hematological malignancies, even the elderly and those with major organ dysfunctions, might benefit from reduced intensity transplantation. | en |
dc.language.iso | en | - |
dc.publisher | Korean Academy of Medical Science | en |
dc.subject | Adolescent | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Busulfan/*administration & dosage | en |
dc.subject | Female | en |
dc.subject | Hematologic Neoplasms/*therapy | en |
dc.subject | Hematopoietic Stem Cell Transplantation/*methods | en |
dc.subject | Humans | en |
dc.subject | International Cooperation | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Myeloablative Agonists/*administration & dosage | en |
dc.subject | Transplantation Conditioning/*methods | en |
dc.subject | Transplantation, Homologous/methods | en |
dc.subject | Treatment Outcome | en |
dc.subject | Vidarabine/administration & dosage/*analogs & derivatives | en |
dc.title | Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 김인호 | - |
dc.contributor.AlternativeAuthor | 이경훈 | - |
dc.contributor.AlternativeAuthor | 최윤희 | - |
dc.contributor.AlternativeAuthor | 김범석 | - |
dc.contributor.AlternativeAuthor | 구남희 | - |
dc.contributor.AlternativeAuthor | 윤성수 | - |
dc.contributor.AlternativeAuthor | 유근영 | - |
dc.contributor.AlternativeAuthor | 박선양 | - |
dc.contributor.AlternativeAuthor | 김병국 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.